Articles, news releases, industry coverage and commentary.
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. – February 20, 2024 – Charles River
Pluristyx and Resilience Form Partnership to Accelerate the Development of Promising Stem Cell Therapies
Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells (iPSCs) and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines today, today announced
SEATTLE, WA - December 21, 2023 - Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major
Stem Genomics Announces Partnership with Pluristyx, Leading One-Stop-Shop Solution Provider for High-Quality Cell-Based Therapies.
Pluristyx, Inc. and Stem
Genomics SAS today announce the closing of an equity investment and strategic partnership in Stem Genomics. Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent stem cell (PSC) lines using Stem Genomics’ iCS-digital™ PSC assay.
Pluristyx and the Advanced Regenerative Manufacturing Institute to Commercialize Clinical-Grade Stem Cells
Pluristyx, Inc. today announced an agreement with the
Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and
commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
This collaboration will make it possible to accelerate the scalable, consistent, and cost-effective
manufacturing of stem cell derived products for patient administration.
Pluristyx/panCELLa Become Industry Resource Partner with the California Institute for Regenerative Medicine
The partnership will improve access to clinical-grade genetically-modified induced pluripotent stem cells June 12, 2023 – Seattle – Pluristyx and panCELLa, a merged biotechnology company with offices in Seattle, WA
Accelerating the Development of
Advanced Cell Therapies | PanCELLa is a pioneering company in the development of pluripotent stem cells and gene editing technology for creating “off-theshelf” cell therapies.
May 12, 2023 – Seattle, Washington and Guimarães, Portugal – Pluristyx and Stemmatters are excited to announce a new partnership to accelerate the development of induced pluripotent stem cell (iPSC)-derived advanced therapies.
BioCentriq and panCELLa Execute Research Agreement to Study Stem Cell-derived Natural Killer Cell Expansion Technology
May 2, 2023 - BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa’s genetically-engineered, induced Pluripotent Stem
Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology
panCELLa granted patent in the United Kingdom for induced Allogeneic Cell Tolerance (iACT Stealth™) Technology January 12, 2023 – Toronto – Pluristyx and panCELLa today are excited to announce the granting
Pluristyx and Blood Cell Storage, Inc. announces partnership to create An Automated Cell Differentiation Monitoring System for use in Tissue Engineered Medical Product (TEMP) Manufacturing.
August 2, 2022; Seattle Washington: Blood Cell Storage Inc (BCSI), a medical device company whose products help assure the quality of platelet transfusions and help optimize the environment for embryo
Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells (hTSCs)
Accelerated Biosciences’ ethically sourced stem cells will be available for clinical product development in Q3 2022 SEATTLE, WA. – APRIL 26, 2022 – Pluristyx, Inc. Pluristyx, Inc., an advanced therapy
Pluristyx, panCELLa, and Implant Therapeutics announce a strategic alliance to manufacture and distribute genetically-modified, clinical-grade human-induced pluripotent stem cells
Improved access to induced pluripotent stem cells for allogeneic cell therapy applications SEATTLE, WA. – JANUARY 20, 2022 – Pluristyx, Inc. Pluristyx, Inc., an advanced therapy tools and services biotechnology
TORONTO, Jan. 8, 2021 /CNW/ - panCELLa's intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics. Implant Therapeutics,
TORONTO, April 21, 2020 /CNW/ -Toronto-based panCELLa and CCRM have executed a collaboration agreement using novel technology to generate commercial-use and clinical-grade iPSC lines which will be made available to academia and
TORONTO, April 7, 2020 /CNW/ - panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help
TORONTO, April 3, 2020 /CNW/ - panCELLa is pleased to announce that it has extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the
Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa
Hamburg, Germany, and Toronto, Canada, 02 April 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered
Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy
MELBOURNE, Australia and TORONTO, Feb. 12, 2019 /CNW/ - Cartherics Pty Ltd ("Cartherics") and panCELLa Inc. ("panCELLa") are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer
TORONTO, Nov. 14, 2018 /CNW/ - panCELLa is proud to announce the publication of "Linking a cell division and a suicide gene to define and improve cell therapy safety" in the November 21st 2018 issue of Nature.
panCELLa Inc., an innovative biotechnology company, has announced today the recent completion of a $1M investment from Chiefswood Holdings Limited. Terms of the financing were not disclosed. This is the first outside capital for the company.